Microbion Corporation is a clinical-stage biopharmaceutical company based in Vancouver, BC and Bozeman, MT, led by Chairman & CEO Karim Lalji. The company’s lead compound, MBN-101, has a dual antimicrobial action that attacks both bacteria and related microbial biofilms. Microbion intends to use its latest funding to initiate and complete a Phase 1B/2A study in diabetic foot ulcer infections, evaluating safety and efficacy endpoints including eradication of infections and biofilms. In 2016 the FDA granted MBN-101 Qualified Infectious Disease Product (QIDP) and Fast Track designations for adjunctive treatment of moderate and severe diabetic foot ulcer infections. The article reports a US$25m financing from Quark Venture Inc. through its Global Health Sciences Venture Fund. No operating metrics beyond the financing amount were disclosed in the article.

Total raised

$25M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2017